Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Labrador who wrote (1776)	12/31/2001 5:05:37 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 2515

Lab, I don't think the rumor tag can be placed on this issue. The FDA has very clear rules and everyone knows that they have 60 days to respond to a filing request. The big Wall Street firms and analyst keep a close eye on the daily filings and issuances coming from the FDA and biotech firms. It was no secret that IMCL apparently had problems because everyone paying attention knew the time was coming to an end of the 60 day time frame. Remember! The CEO had clearly stated that because of the way they filed their documents it allowed them the opportunity to work closely with the FDA on each step of the process...therefore, the CEO had to have known that something wasn't right before last Friday night....or it means that their efforts to work close with the FDA was a bogus claim in the first place...or it means the FDA had it out for IMCL and colon cancer patients. Which do you believe?

To: Labrador who wrote (1776)	1/7/2002 8:37:32 AM
From: Arthur Radley	Respond to of 2515

Seems that what I was suggesting back in December is NOW coming true.. "On. Dec. 31, U.S. regulators said they would not accept the firm's application to sell the colon cancer drug, which is being co-promoted with Bristol-Myers Squibb Co. (NYSE:BMY - news). Details of the U.S. Food and Drug Administration's refusal-to-file letter were released on Friday in The Cancer Letter, an industry newsletter. ``We believe the details disclosed in The Cancer Letter article suggest additional deficiencies in ImClone's biological license application (BLA) beyond those already disclosed by the company in its conference call on December 31,'' J.P. Morgan said in a research note